CYTK

NASDAQ · Biotechnology

Cytokinetics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$67.59

+0.03 (+0.04%)

As of Sep 22, 9:48 PM ET ·

CYTK News1 articles

Cytokinetics Drops 5% Despite Positive Phase 3 Data in nHCM

Cytokinetics shares slid 5% despite positive Phase 3 trial results for MYQORZO in non-obstructive HCM, as investors hoped for larger clinical benefits.